Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[C-11]MENET is a radiolabeled compound used as a positron emission tomography (PET) imaging agent for the norepinephrine transporter. It is labeled with carbon-11 and designed to visualize and quantify norepinephrine transporter density in vivo. The compound acts as a selective ligand for the norepinephrine transporter, making it useful in neuroimaging studies of diseases involving noradrenergic dysfunction such as depression, Parkinson’s disease, and other neuropsychiatric or neurodegenerative disorders. The mechanism of action involves binding to the SLC6A2 protein (norepinephrine transporter), allowing PET imaging of its distribution and density in the brain[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [C-11]MENET.